A Revolution in
Eye Disease Treatment

At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

He also oversees the preclinical and clinical development of each of the company’s products. In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs. David received a BS in Microbiology from the University of Maryland and an MD from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.

In this role, Ms. Bauerlein oversaw the global finance and accounting functions, including revenue management, financial planning and analysis, strategic and tactical cost analysis and forecasting, treasury, SEC reporting, investor relations, business development, risk management, tax, and treasury functions, as the Inogen scaled from start-up operations to over $350 million in annual sales. Ali has also served as a member of the board of directors of Pear Therapeutics, Inc, a software-based digital therapeutics company, since December 2021, and as a member of the board of directors of Gelesis Holdings, Inc, a biotherapeutics company since January 2022. She serves as chair of the Audit Committees of both Pear and Gelesis. Ms. Bauerlein also serves as a member of the board of directors of Koya Medical, Inc., a private company, since January 2021. Ali received a B.A. in economics/mathematics with high honors from the University of California, Santa Barbara.

He has been in practice in Atlanta since 1988. Dr. Brown has published more than 90 peer reviewed articles on glaucoma and cataract surgery. He has served as chairman of the ASCRS Glaucoma Committee and is currently the Glaucoma Editor of EyeWorld magazine. He recently received the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Brown is one of only a few ophthalmologists in Georgia to receive this prestigious award. He received the 2013 Distinguished Alumnus Award from John Hopkins University (Wilmer Eye Institute) and the 2014 Innovator Award form the American Glaucoma Society. He has given many named lectures all over the world including the Obstbaum Lecture at the 2011 ASCRS Glaucoma Day. He was selected to give the Charles D. Kelman Innovator Lecture in 2017. This international award honors Dr. Kelman, the inventor of phacoemulsification, a huge step forward in successful cataract surgery outcomes. This award has only been given to 33 innovators in eye surgery since its inception in 1985.

Dr. Brown and his wife, Dr. Mary G. Lynch, a Professor at Emory, have been awarded 25 patents for new devices and instruments to improve glaucoma and cataract surgery. Their patents on trabecular bypass are the fundamental patents for several innovative devices implanted into the outflow channel of the eye. Dr. Brown has been selected by his peers to be listed each year in Best Doctors in America and by a separate peer survey in Atlanta Magazine as one of the best ophthalmologist in Atlanta.

Dr. Brown earned his undergraduate degree from Harvard College Cum laude and completed medical school at the University of Michigan. He trained in ophthalmology at the Wilmer Eye Institute of Johns Hopkins University. He then completed a glaucoma fellowship at the Bascom Palmer Eye Institute and returned to Johns Hopkins as Chief Resident.

Dr. Brown was selected as the first Pamela Firman Professor of Ophthalmology at the Emory Eye Center. Mrs. Firman made the donation for the professorship in gratitude for Dr. Brown’s care of her eyes. He served as the Director of the Glaucoma Service at Emory for eleven years prior to entering private practice with Atlanta Ophthalmology Associates in 1999.

Drs. Brown and Lynch have two daughters, Veronica and Annie. Rounding out their household is, Lily, a loving English Mastiff. Dr. Brown is an avid runner, enjoys playing tennis and traveling with his family.

Before Orion, Mr. Link spent nearly 15 years in regional and executive leadership positions at NuVasive Inc., a global leader in surgical implants and enabling technology for spine surgery and orthopedics, where he designed and executed strategies that supported the company’s revenue growth from less than $100 million to over $1 billion. Mr. Link joined NuVasive as an Area Business Manager and rose to the level of President where his responsibilities included oversight of global business units in spine, neurophysiology and orthopedics. Prior to NuVasive, Mr. Link held commercial leadership roles at Depuy Orthopedics and Depuy Spine. He currently serves as a member of the board of directors of Springbok Analytics, Fibrobiologics and DinamicOR. Additionally, he serves on the board of directors for the Coulter Translational Research Endowment at the University of Virginia. Mr. Link received a BSEd in Physical Education and Sports Medicine from the University of Virginia.

Prior to joining Sight Sciences, Mr. Buckley led Medeon's commercial operations strategy. Prior to that he served as Vice President of Global Marketing and Business Development at Iridex Corporation until 2019. He held a number of key leadership positions of increasing responsibility, including executive leadership of US and global sales. Throughout his career, Mr. Buckley has focused on both early stage market development and global commercialization with expertise in launch strategy. Prior to Iridex, he was co-founder and CEO of Ocunetics, Inc. an early stage ophthalmic start-up. Mr. Buckley joined Iridex through its acquisition of Ocunetics’ technologies. He previously worked at Transcend Medical (acquired by Alcon), an ophthalmology stent start-up, and at Carl Zeiss Meditec where he led the marketing for its North American ophthalmic surgery division. Prior to 2001, Mr. Buckley gained extensive experience developing innovative devices in a product development capacity at Starion Instruments (acquired by Microline Surgical), General Surgical Innovations (acquired by Tyco Healthcare), and Lockheed Martin. Mr. Buckley holds a BS in Mechanical Engineering from the University of California, Berkeley and an MBA in Business from Santa Clara University

Prior to joining Sight Sciences, Mrs. Cantu lead the Health Economics and Market Access activities for Joint Reconstruction at Johnson & Johnson. Prior to that she served as Sr. Director of Global Market Access for Glaukos where she led a team that achieved a number of key positive decision and successes, such as obtaining positive HTAs, coverage decisions and access to important markets such as France, Brazil, and other Latin America, European and Asian markets. Prior to that, she held similar roles at Becton Dickinson and a long-standing career at Alcon.

Mary’s passion for developing teams, engaging with multiple stakeholders such as payers, providers and specialty societies has led to opportunities to collaborate and develop successful market access strategies. Mary’s experience in US reimbursement, coverage, and coding as well as her experience in navigating international markets will have a positive impact on our strategies at Sight Science.

Mary holds a BS in Business Management and a Master of Science in Health Care Administration from the University of Texas at Arlington.

Kathy has served as Head, Global Regulatory Affairs at Alcon in Fort Worth, Texas, for its Vision Care franchise (contact lenses, solutions, and intraocular lenses) as well as head of regulatory at one of their Surgical division’s facilities focusing on Excimer laser devices for corrective surgery (LASIK). From 2002 to 2014, she served in various leadership roles in Regulatory, Quality, and Clinical Affairs for St. Jude Medical (now Abbott) for products including: cardiac pacemakers, implantable defibrillators, and spinal cord stimulators with her last position held as Corporate Officer/Vice President, Global Regulatory. She holds a bachelor’s degree in Biomedical Engineering from Tulane University in Louisiana and the Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

Dr. Dickerson is the author of ~60 peer-reviewed publications in the fields of biochemistry, clinical ophthalmology, and chronic wounds and is a reviewer for several journals in the fields of ophthalmology and wound healing.

Dr. Dickerson received B.S. (Biology), B.A. (Chemistry), and M.S. (Biology) degrees from the University of Texas at Arlington, and his Ph.D. degree (Biomedical Sciences-Biochemistry) from the University of North Texas Health Science Center where he holds an adjunct Associate Professor appointment with the North Texas Eye Research Institute.

Over the course of her career Laurie has held field sales roles, served as a technical trainer in multiple geographies and ultimately took on expanded executive leadership roles in both internal sales training and external customer education.

Laurie has led training efforts in organizations ranging in yearly revenue from $240M to over $5.5B in global sales with a track record of leading functions that certify nearly 1000 cardiovascular physicians globally/year and train an average of nearly 500 field reps/year.

Laurie’s passion for bringing forward programs and educational initiatives that enable sales has led to opportunities throughout her career to build multiple training organizations that maximize individual contributions and enhance team impact. Laurie’s experience in creating customized education solutions, her dedication to cross-functional partnerships, and her passion for customer engagement and physician advocacy development will translate well to the field of ophthalmology.

Prior to that Jeff was at Alcon Laboratories, a global leader in Ophthalmology, where he held positions of increasing responsibility in sales, sales leadership, marketing, training, and hospital/corporate account leadership. Most recently, Jeff held the position of VP of Glaucoma Sales at Sight Sciences where he built the US Surgical Sales infrastructure from the ground up. Throughout his career Jeff has demonstrated passion and excellence with a rich history of building, developing and empowering high performing cultures. He is deeply committed to advancement of eye care. Jeff holds a bachelor’s degree from the University of Kansas.

He was responsible for building out the US Structural Heart Commercial Finance, Sales Operations, and Customer Service functions. During this time, the business more than doubled through new product launches, indication expansion, and other portfolio enhancements. Prior to that, Kole held various roles at St. Jude Medical in Finance, Sales Operations, and Internal Audit. He began his career at RSM in the audit and assurance practice.

Kole holds degrees in Finance and Accounting from Concordia University (St. Paul) and is a Certified Public Accountant (inactive).

Since 2012, Jeremy has worked exclusively in senior legal positions for innovative medical device companies, including serving as Assistant General Counsel for Volcano Corporation, General Counsel and Vice President of Business development for Cytori Therapeutics, Inc. and General Counsel for Endologix, Inc. Jeremy holds a J.D. from University of Michigan Law School and an A.B. in Politics from Princeton University.

Rob has built a strong personal and professional network of global Key Opinion Leaders and commercial partners while building and managing commercial infrastructure that contributed to the creation of world leading markets for multiple innovation driven enterprises.

Rob brings an extensive amount of leadership and business acumen, specifically in the global markets, to the Sight Sciences leadership team. Rob holds a degree in Business Administration & Finance from Coventry University, UK.

Todd joined Sight Sciences from Bausch + Lomb where he was Director, Professional Strategy and led the development of key opinion leaders, optometric institutions and professional programs. Prior, Todd held positions of increasing responsibility at Alcon Laboratories in sales, sales leadership, market development, global marketing and brand management where he led the company’s global contact lens care franchise. During his tenure at Alcon, he was awarded PM360’s Trailblazer Award for Industry Wide Marketing Innovation. Todd holds a bachelor’s degree in business administration from the University of Houston.

Prior to joining Sight Sciences, Dave was VP of R&D at Meditrina Medical developing and launching a 510(k)-cleared hysteroscope & tissue resection system. Other roles include Director of R&D at BAROnova producing a PMA-approved weight loss therapy, developing and manufacturing novel spinal implants (Benvenue Medical), urological access and treatment devices (Percutaneous Systems), and articulating laparoscopic surgical instruments (Pivotal Medical).

Dave holds a degree in Mechanical Engineering from Brown University.

Prior to joining Sight Sciences and entering the world of ophthalmology, Daniel amassed over ten years of successful research and development product development experience in cardiovascular catheters, vascular surgery delivery systems and surgical instruments. Daniel has designed and developed innovative products for industry leaders such as Boston Scientific and smaller start-ups such as Aptus Endosystems. Daniel received a BS in Mechanical Engineering from the California Polytechnic State University, San Luis Obispo.

He joined Sight Sciences in 2019 from Alcon Laboratories where he held positions of increasing responsibility in sales, sales leadership, training, marketing, and marketing leadership both domestically and internationally. During his tenure at Alcon, Mark received numerous awards for the achievement of commercial objectives. Most recently, Mark held the position of National Account Director at Sight Sciences where he built the Academic team and the Corporate Account team. He brings a passion for building high performing, empowered teams and a strong commitment to the advancement of the glaucoma space. Mark holds a bachelor’s degree from Texas Christian University.

He also led operations at Novacept from early revenue to its acquisition by Cytyc. Sam has held various other executive and technical positions at Spineview (Expending Innovation), Arthrocare (acquired by Smith and Nephew), CardioGenesis (IPO), and Origin Medsystems (acquired by Eli Lily, later Guidant).

Before entering the medical device industry, Sam worked in aerospace at Hughes Aircraft, and Xerox Designing and Manufacturing Laser Systems.
Sam hold a BS from the University of California Irvine in Mechanical Engineering.

Before joining Sight Sciences, Chris was Vice President of IT and CIO at Allstream, a North American telecommunications and connectivity provider with responsibilities for the network architecture, technology innovation and network operations teams. Chris has more than 20 years’ experience driving IT, Security, Process, and Operational improvement programs. He is a strategic innovator adept at defining, designing and commercializing leading edge technologies. He has a degree in IT and Finance from Oregon State University.

Regan was an executive committee member and marketing organization leader during his more than 10 years with TearScience, and through this work, is considered one of the thought leaders in the development of the evaporative dry eye market. Regan will be leveraging his broad industry experience to lead strategy across both the Surgical and Dry Eye businesses, with a focus on the company’s interactions with key opinion leaders within the Ophthalmology and Optometry specialties.

Prior to that, Jim was Director of Finance at Abbott Laboratories in the $10B+ medical device division and spent 8 years in several progressive finance and accounting roles at St. Jude Medical (prior to its acquisition by Abbott). He began his career at Deloitte in the audit and assurance practice.

Jim holds a BS in Accounting from the University of Minnesota and is a Certified Public Accountant (inactive).

Pierre started his career with Alcon in 2008, and over his tenure excelled in many core positions. These positions included increasing responsibility in people leadership, KOL development, and global marketing. Pierre earned multiple President’s/Master’s clubs, Circle of Excellence, and Leadership Awards. His most recent responsibilities at Alcon included global marketing for Alcon’s core surgical portfolio. He has a passion for mentoring, developing talent, changing market treatment paradigms, as well as creating long lasting partnerships with surgeons & KOLs.

With a highly successful track record in developing and delivering high-quality products and commercial launch readiness programs, Pierre has led cross-functional, high-performing teams to execute strategy, develop solutions, drive projects to completion, and build programs in alignment with executive objectives. Additionally, Pierre was the Chair of Alcon’s AACE (African Ancestry Cultivating Excellence) organization, an employee resource group focused on enhancing the culture of Diversity & Inclusion for all employees while ensuring equitable opportunities for advancement and development.

Pierre holds two Bachelor’s Degrees in Marketing & Finance, and an MBA with a focus in Business Portfolio Development & Sales Leadership. Additionally, Pierre holds an International Degree in Economics, from Charles University- Prague, Czech Republic. He is a two-time published author, a TEDx speaker, and sits on the board for North Dallas ISD, mentoring students on key topics such as financial literacy, transitions into university studies, working in “Corporate America”, etc.

During his 23 year tenure at Alcon, he held escalating positions of leadership in sales, managed markets, domestic marketing, global marketing and finally Head of U.S. Pharmaceutical Marketing before moving to the global leader in dermatology, Galderma, as Vice President of U.S. Prescription marketing.

Jim earned his bachelor’s degree from the University of Pittsburgh.

Prior to joining Sight Sciences, Inc., Steve was the Surgical Franchise Compliance Head, US & Global Surgical Integrity & Compliance at Alcon Vision, where he was responsible for the overall direction and implementation of the Company’s Integrity & Compliance program for the Surgical Franchise of Alcon Vision.

Steve earned a bachelor’s degree in Sociology from the University of California, Santa Barbara and a law degree from the University of Oregon Law School and is a member of the New Jersey Bar.